Coupons.Com Inc (NYSE: COUP) is the most recent small cap digital coupon or daily deal stock to emerge in a spectacular IPO to challenge existing players like mid cap Groupon Inc (NASDAQ: GRPN) and small caps LiveDeal Inc (NASDAQ: LIVE) and RetailMeNot Inc (NASDAQ: SALE). However and since the recent IPO, small cap Coupons.Com has been a relatively flat deal for investors.
What is Coupons.Com Inc?Small cap Coupons.Com calls itself a leader in digital coupons that�operates a promotion platform that connects brands and retailers with consumers through Web, mobile and social channels. Over 2,000 brands from more than 700 consumer packaged goods companies and many grocery, drug and mass merchandise retailers use Coupons.Com�� platform to deliver digital coupons to consumers, including printable coupons, save-to-card coupon and coupon�codes for e-commerce.�Coupons.Com also sells advertising for�its online and mobile properties and has built�out a�large network of retailers and publishers spanning more than �58,000 store locations in North America and approximately 30,000 third-party websites. The Coupons.com�� site itself�receives more than 17 million unique visitors a month on average.
Top 10 Restaurant Stocks To Invest In Right Now: Hillenbrand Industries Inc. (HRC)
Hill-Rom Holdings, Inc. manufactures and provides medical technologies and related services for the health care industry worldwide. It offers patient support system, safe mobility and handling solutions, medical equipment rental services, surgical products, and information technology solutions, as well as non-invasive therapeutic products for acute and chronic medical conditions. The company rents and sells patient support systems, which include various bed systems, and integrated and non-integrated therapeutic bed surfaces for use in high, mid, and low acuity settings; and non-invasive therapeutic products and surfaces for the prevention and treatment of various acute and chronic medical conditions, including pulmonary, wound, and bariatric conditions. It also provides rentals and health care provider asset management services for moveable medical equipment, such as ventilators, defibrillators, intravenous pumps, and patient monitoring equipment; mobility solutions, inclu ding lifts and other devices used to move patients; architectural products comprising headwalls and power columns; and health care furniture solutions. In addition, the company develops and markets various communications technologies and software solutions primarily to improve patient safety at the point of care; and surgical products, including a range of positioning devices for use in shoulder, hip, spinal, and lithotomic surgeries, as well as platform-neutral positioning accessories for operating room tables. It sells its products primarily to acute and extended care health care facilities through direct sales force and distributors. The company was formerly known as Hillenbrand Industries, Inc. and changed its name to Hill-Rom Holdings, Inc. in March 2008. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Batesville, Indiana.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Hill-Rom Holdings (NYSE: HRC ) , whose recent revenue and earnings are plotted below. - [By Lisa Levin]
Hill-Rom Holdings (NYSE: HRC) dropped 14.43% to $37.74 after the company reported weaker-than-expected Q1 results and lowered its outlook. The company also announced its restructuring program.
- [By Stephen Simpson, CFA]
On the antennas side, PCTEL antennas can be used in a wide variety of applications from mobile radio to WiFi to GPS and machine-to-machine communication. PCTEL management defines the company's core addressable market as a 5% to 10% slice of a $30 billion market for process automation, smart grid, public safety, fleet management, and enterprise WLAN. Companies ranging from Harris (HRC) to Deere (DE) to Cisco (CSCO) have used PCTEL antennas, and Cisco incorporates the company's antennas into their higher-end wireless products.
Top 10 Industrial Disributor Stocks To Invest In 2014: Burnham Holdings Inc (BURCA)
Burnham Holdings, Inc., incorporated on December, 2, 2002, is the parent company of the Burnham group of companies. The Company is a manufacturer of boilers, furnaces, radiators, air conditioning systems and related accessories for residential, commercial, and industrial applications. The Company has eight brand names, marketed through eight independent sales organizations that are differentiated by product line and markets served. The Burnham Hydronics, New Yorker, Governale, Thermo Pride, and Crown product lines offer a range of cast iron, stainless steel, aluminum, and steel boilers, cast iron and steel heat distribution products, warm air furnaces, heat pumps and central air conditioning systems for the residential heating and cooling market. Typical applications of these products are for all styles and sizes of homes and small buildings. The Burnham Commercial, Bryan Boilers, and Thermal Solutions product lines offer a range of cast iron, firetube, watertube, and copper tube boilers, as well as boiler room accessories for the commercial and industrial markets. Typical uses of these products are for heating large buildings and high-pressure steam generation for process applications.
The Burnham Foundry produces boiler castings for the affiliated manufacturing companies, as well as outside customers. Wendl and Manufacturing is a producer of both pressurized and non-pressurized tanks and vessels for liquid storage applications. Norwood Manufacturing is a manufacturer of painted light gauge metal parts. The Company sells to wholesale distributors who in turn, market to builders, heating contractors, utilities, and fuel dealers for resale to end-use customers.
Advisors' Opinion:- [By Marc Bastow]
Boiler, radiator, air conditioning and furnace manufacturer Burnham Holdings (BURCA) raised its quarterly dividend 11% to 21 cents per share, payable March 18 to shareholders of record as of March 11.
BURCA Dividend Yield: 4.3%
Top 10 Industrial Disributor Stocks To Invest In 2014: Conmed Corp (CNMD)
CONMED Corporation (CONMED), incorporated on February 10, 1970, is a medical technology company/ The Company emphasizes on surgical devices and equipment for minimally invasive procedures and monitoring. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The Company operates in five segments: CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec and CONMED Patient Care.
Arthroscopy
The Company offers a range of devices and products for uses in arthroscopic surgery. The Company's arthroscopy products include powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bioabsorbable implants as well as related disposable products and fluid management systems. The Company also offers a line of video Endoscopy products suitable for uses in multi-specialty clinical environments beyond orthopedic arthroscopy, including laparoscopy, ear, nose and throat (ENT), gynecology and urology, as well as integrated operating room systems and equipment.
Powered Surgical Instruments
Electric, battery or pneumatic powered surgical instruments are used to perform orthopedic, arthroscopic and other surgical procedures where cutting, drilling or reaming of bone is required. Each power system consists of one or more handpieces and related accessories as well as disposable and limited reusable items (e.g., burs, saw blades, drills and reamers). Powered instruments are categorized as either small bone, large bone or specialty powered instruments. Specialty powered instruments are utilized in procedures such as spinal surgery, neurosurgery, ENT, oral/maxillofacial surgery, and cardiothoracic surgery.
The Company's line of powered instruments is sold principally under the Hall Surgical brand name, for use in large and small bone orthopedic, arthroscopic, oral/maxillofaci! al, podiatric, plastic, ENT, neurological, spinal and cardiothoracic surgeries. Large bone, neurosurgical, spinal and cardiothoracic powered instruments are sold primarily to hospitals while small bone arthroscopic, otolaryngological and oral/maxillofacial powered instruments are sold to hospitals, outpatient facilities and physicians offices.
The Company's powered instruments product line includes the MPower battery system. This orthopedic power system is specifically designed to meet the requirements of orthopedic applications. The MPower battery system allows a facility to purchase a single power system to perform total joint arthroplasty, trauma, arthroscopy, and small bone procedures. The system also provides a multitude of battery technologies to meet the varying needs of hospitals worldwide.
Electrosurgery
The use of electrosurgical units and associated surgical tools is commonplace in the hospital surgical suite, surgery centers, clinics and physician offices. Electrosurgery is routinely used to cut and coagulate tissue and small vessels in open and laparoscopic procedures using energy produced through radio frequency (RF) technology. Electrosurgery can be used in almost all surgical procedures including specialties, such as general, gynecology, orthopedics, cardiology, thoracics, urology, neurology, and dermatology. The Company�� portfolio consist of energy-based products is the Argon Beam Coagulation (ABC) technology. ABC technology combines the use of argon gas and electrosurgical energy to allow the surgeon to produce a surface coagulation which results in less tissue damage.
Patient Care
The Company's patient care product line includes a line of vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, electrocardiogram (ECG) electrodes and cables, cardiac defibrillation and pacing pads and blood pressure cuffs. The Company also offers a line of suction instruments and tubing for use in the! operatin! g room, as well as a line of intravenous (IV) products for use in the critical care areas of the hospital.
Endosurgery
Endosurgery (also referred to as minimally invasive surgery or laparoscopic surgery) is surgery performed without a incision. The Company's Endosurgical products include the Reflex and PermaClip clip appliers for vessel and duct ligation, Universal S/I (suction/irrigation) and Universal Plus laparoscopic instruments and specialized suction/irrigation electrosurgical instrument systems for use in laparoscopic surgery. The Company also offers cutting and dilating trocars, suction/irrigation accessories, laparoscopic scissors, dissectors and graspers, active electrodes, insufflation needles and linear cutters and staplers for use in laparoscopic surgery. The Company's disposable skin staplers are used to close large skin incisions with surgical staples, thus eliminating the time consuming suturing process. CONMED Endosurgery also offers a uterine manipulator called VCARE for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures.
Endoscopic Technologies
The Company offers a line of minimally invasive diagnostic and therapeutic products used in conjunction with procedures, which requires flexible endoscopy. The Company's principal customers include gastrointestinal (GI) endoscopists, pulmonologists, and nurses who perform both diagnostic and therapeutic endoscopic procedures in hospitals and outpatient clinics.
The Company's primary focus is to identify, develop, acquire, manufacture and market differentiated medical devices, which improve outcomes in the diagnosis and treatment of gastrointestinal and pulmonary disorders. The Company's diagnostic and therapeutic product offerings for GI and pulmonology include mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and ! polypecto! my.
The Company competes with Smith & Nephew, plc, Arthrex, Inc., Stryker Corporation, ArthroCare Corporation, Johnson & Johnson: DePuy Mitek, Inc., Biomet, Inc., Medtronic, Inc. Midas Rex and Xomed, Synvasive Technology, Inc., Synthes, Inc., MicroAire Surgical Instruments, LLC, Zimmer Holdings, Inc., Covidien Ltd.; Valleylab, Medline Industries, Inc., ERBE Elektromedizin GmbH, Megadyne, Kendall, 3M Company, Ethicon Endo-Surgery, Inc, U.S.Surgical, Boston Scientific Corporation, Wilson-Cook Medical, Inc, Olympus America, Inc. and STERIS Corporation.
Advisors' Opinion:- [By James Brumley]
Shares of MDT stock have fallen 6% since their early January peak, but have been in an uptrend since late 2011 … one of the few stocks in the medical device world that has been rock-solid in a rocky environment.
Medical Devices: ConMed Corp. (CNMD)With a market cap of only $1.2 billion, ConMed Corp. (CNMD) isn’t exactly a household name. That doesn’t mean CNMD stock can’t be a potent addiction to a portfolio, though.
- [By ovenerio]
In the medical devices business (83% of FY 13 sales), the company competes with good health care companies such as Johnson & Johnson (JNJ), C.R. Bard (BCR) and ConMed (CNMD).
Top 10 Industrial Disributor Stocks To Invest In 2014: Hersha Hospitality Trust (HT)
Hersha Hospitality Trust, a real estate investment trust, engages in the ownership and operation of mid scale limited service hotels in the Eastern United States. As of June 30, 2005, it owned interests in 35 hotels, including 4 hotels owned through joint ventures in Pennsylvania, New York, New Jersey, Maryland, Georgia, Connecticut, and Massachusetts. The company has elected to be taxed as a REIT under the Internal Revenue Code. As a REIT, Hersha would not be subject to income tax to the extent it distributes at least 90% of its taxable income to its stockholders. The company was founded in 1998 and is headquartered in New Cumberland, Pennsylvania.
Advisors' Opinion:- [By George Putnam]
Steve Halpern: Now, you've also looked at a company called Hersha Hospitality (HT). How are they involved in the industry?
George Putnam: Well, Hersha, again, has been refocusing its business. It was a little unfocused before. It had both a suburban and urban market, and it's recently agreed to sell the last of its suburban properties.
Top 10 Industrial Disributor Stocks To Invest In 2014: Redcliffe Resources Ltd (RCF)
Redcliffe Resources Limited, formerly Pacrim Energy Limited, is engaged in gold exploration. The Company own 100% interest in Redcliffe Gold Project. The Redcliffe Gold Project lies northeast of the mining town of Leonora, which is 230 kilometer north of Kalgoorlie in Western Australia. The Project covers approximately 45 kilometers of strike length of the Mertondale Shear Zone (MSZ) along with parallel and associated structures. The Golden Terrace South (GTS) deposit lies within a granted mining lease in the southern portion of the Redcliffe Gold Project. The 727 Prospect is located less than five kilometer south east of Golden Terrace. The Kelly Prospect lies along the Mertondale Shear Zone some three to four kilometer north of Golden Terrace South. Advisors' Opinion:- [By Tom Stoukas]
Teleperformance SA (RCF) climbed 2.9 percent to 35.10 euros. Societe Generale SA raised its recommendation on the French operator of call centers to buy from hold. The brokerage said the shares��recent decline provides a buying opportunity. The stock has fallen 14 percent since its high on July 18.
Top 10 Industrial Disributor Stocks To Invest In 2014: Stemline Therapeutics Inc (STML)
Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.
SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.
SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk
SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.
SL-701
SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.
StemScreen-1
StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.
StemScreen-2
StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.
The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.
Advisors' Opinion:- [By David Zeiler]
3. Stemline Therapeutics Inc. (Nasdaq: STML): This biotech develops drugs that target cancer stem cells and tumors. Stemline went public January 29 at $10 a share and rose just 11.78% on its first day. But STML has climbed steadily since, and currently trades at $37.46, up 274.6% from its IPO price.
- [By Keith Speights]
Best-performing biotech IPO
Stemline Therapeutics� (NASDAQ: STML ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%. - [By Jay Silverman]
Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.
Top 10 Industrial Disributor Stocks To Invest In 2014: Revive Therapeutics Ltd (RVV)
Revive Therapeutics Ltd., formerly Mercury Capital II Limited, is focused on acquiring, developing and commercializing treatments for major market opportunities such as sleep apnea, gout and rare diseases. The Company is focused on underserved medical needs such as opioid-induced respiratory depression in high risk patients with sleep apnea, gout, and Rett Syndrome. The Company is also developing a next generation analog of REV-001, which is an improvement of the original compound and it will have the potential to treat new diseases that would otherwise remain untreated with the original compound, such as rare diseases, breathing disorders, and cognitive dysfunction. Advisors' Opinion:- [By Holly LaFon]
Whitney George is Director of Investments, Managing Director, and a Portfolio Manager of Royce & Associates, LLC, investment advisor to The Royce Funds. He serves as portfolio manager for Royce Premier Fund (RPR), Royce Low-Priced Stock Fund (RLP), Royce Global Value Fund (RGV), Royce SMid-Cap Value Fund (RSV), and Royce Focus Trust (FUND). He also serves as assistant portfolio manager for Royce Micro-Cap Fund (RMC), Royce Value Fund (RVV), Royce Value Plus Fund (RVP), Royce Focus Value Fund (RFV), and Royce Capital Fund ��Micro-Cap Portfolio (RCM). Mr. George's thoughts in this interview concerning the stock market are solely his own and, of course, there can be no assurance with regard to future market movements.
No comments:
Post a Comment